Subtype
Astrocytic Tumor
CI-CAN-00001839Explore in graph →
Non-malignant507 active trials2 approved drugs67 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001839Explore in graph →
Clinical trials
1,861 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05911230 | Advanced Diffusion MRI to Differentiate Tumor Recurrence From Pseudoprogression in Patients With Glioblastoma and Brain Metastases(AiD-GLIO) | recruiting | N/A | 10 | University Hospital, Basel, SwitzerlandOTHER | 1 | Jan 29, 2025 | clinicaltrials |
| NCT06710249 | Impact of Salovum® and SPC® Flakes on Brain Tumor Induced Edema(AFBTEdema) | recruiting | Phase 2 | 20 | Peter SiesjöOTHER | 1 | Jan 27, 2025 |
| clinicaltrials |
| NCT06780592 | Vebreltinib Combined With Temozolomide for Glioblastoma (GBM) After Surgery | not yet recruiting | Phase 2 | 60 | Huashan HospitalOTHER | 0 | Jan 22, 2025 | clinicaltrials |
| NCT06097975 | A Clinical Trial on Combined (Neo-)Adjuvant Intravenous Plus Intracranial Administration of Ipilimumab and Nivolumab in Recurrent Glioblastoma(NEO-GLITIPNI) | recruiting | Phase 1 | 18 | Universitair Ziekenhuis BrusselOTHER | 1 | Jan 20, 2025 | clinicaltrials |
| NCT06782984 | Drug Response Testing and Repurposing Using Glioblastoma Organoid | recruiting | — | 150 | Chungnam National University HospitalOTHER | 1 | Jan 20, 2025 | clinicaltrials |
| NCT06764537 | Evaluation of in Vitro Antitumor Activity of GD2 CAR-T Cells in Glioblastoma(BOOSTCAR) | not yet recruiting | N/A | 18 | Central Hospital, Nancy, FranceOTHER | 1 | Jan 8, 2025 | clinicaltrials |
| NCT06757153 | Safety and Efficacy of NRG-103 Injection in the Treatment of Recurrent Glioblastoma Patients | recruiting | Early Phase 1 | 15 | Zhongnan HospitalOTHER | 1 | Jan 3, 2025 | clinicaltrials |
| NCT06740955 | Hypofractionated Radiotherapy | recruiting | N/A | 420 | The First Hospital of Jilin UniversityOTHER | 1 | Dec 18, 2024 | clinicaltrials |
| NCT04195139 | Nivolumab and Temozolomide Versus Temozolomide Alone in Newly Diagnosed Elderly Patients With GBM(NUTMEG) | active not recruiting | Phase 2 | 103 | University of SydneyOTHER | 2 | Dec 11, 2024 | clinicaltrials |
| NCT03395587 | Efficiency of Vaccination with Lysate-loaded Dendritic Cells in Patients with Newly Diagnosed Glioblastoma(GlioVax) | active not recruiting | Phase 2 | 136 | Heinrich-Heine University, DuesseldorfOTHER | 1 | Dec 2, 2024 | clinicaltrials |
| NCT05561374 | Study of Safety and Pharmacokinetic Properties of Oral OKN-007 in Patients with Recurrent High-Grade Glioma | active not recruiting | Phase 1 | 16 | Oblato, Inc.INDUSTRY | 1 | Nov 29, 2024 | clinicaltrials |
| NCT05768919 | Study of Liposomal Curcumin in Combination With RT and TMZ in Patients With Newly Diagnosed High-Grade Gliomas | recruiting | Phase 1 / Phase 2 | 30 | SignPath Pharma, Inc.INDUSTRY | 1 | Nov 29, 2024 | clinicaltrials |
| NCT04648462 | Proton Therapy Research Infrastructure- ProTRAIT- Neuro-oncology | recruiting | — | 1,500 | Maastricht Radiation OncologyOTHER | 1 | Nov 26, 2024 | clinicaltrials |
| NCT04868396 | Patient-derived Glioma Stem Cell Organoids | active not recruiting | — | 60 | Maastricht Radiation OncologyOTHER | 1 | Nov 20, 2024 | clinicaltrials |
| NCT06160206 | Retifanlimab with Bevacizumab and Hypofractionated Radiotherapy for the Treatment of Recurrent Glioblastoma | recruiting | Phase 2 | 134 | Academic and Community Cancer Research UnitedOTHER | 1 | Nov 19, 2024 | clinicaltrials |
| NCT06684899 | Optimizing Cytokine-Induced Killer Cells in Glioblastoma Patients(KillGlio) | not yet recruiting | — | 40 | IRCCS San RaffaeleOTHER | 0 | Nov 14, 2024 | clinicaltrials |
| NCT06640582 | TIL Therapy Combined With Pembrolizumab for Advanced Brain Cancer Including Gliomas and Meningiomas(BAH2472) | recruiting | Phase 1 / Phase 2 | 85 | Essen BiotechOTHER | 1 | Nov 5, 2024 | clinicaltrials |
| NCT01985087 | A Study Using Radiation Therapy and Temozolomide to Treat Glioblastoma in Patients Over 70 | active not recruiting | Phase 1 / Phase 2 | 18 | University of LouisvilleOTHER | 1 | Oct 31, 2024 | clinicaltrials |
| NCT05118776 | Study to Evaluate the Safety and Efficacy of ASC40 Tablets in Combination With Bevacizumab in Subjects With rGBM | active not recruiting | Phase 3 | 136 | Ascletis Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Oct 31, 2024 | clinicaltrials |
| NCT06657027 | Artificial Intelligence-Guided Radiotherapy Planning for Glioblastoma(ARTPLAN-GLIO) | not yet recruiting | — | 40 | Hospital del Rio HortegaOTHER | 0 | Oct 24, 2024 | clinicaltrials |
| NCT00102648 | Lonafarnib and Temozolomide in Treating Patients with Glioblastoma Multiforme That is Recurrent or Did Not Respond to Previous Treatment with Temozolomide | active not recruiting | Phase 1 | 34 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 17, 2024 | clinicaltrials |
| NCT04267978 | Study of Recombinant Human Endostatin Combined with Temozolomide and Irinotecan in Recurrent Gliomas | recruiting | Phase 2 | 109 | Beijing Sanbo Brain HospitalOTHER | 1 | Oct 15, 2024 | clinicaltrials |
| NCT06623565 | Extensive Resection of Malignant Brain Tumors Using Advanced Imaging Techniques(NEXTFRONTIER) | recruiting | N/A | 30 | Amsterdam UMC, location VUmcOTHER | 1 | Oct 2, 2024 | clinicaltrials |
| NCT06616727 | The Safety and Efficacy of SNC-109 CAR-T Cells Therapy the rGBM | enrolling by invitation | Phase 1 | 50 | Shanghai Simnova Biotechnology Co.,Ltd.INDUSTRY | 1 | Sep 27, 2024 | clinicaltrials |
| NCT06595186 | JK-1201I Combined with Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma Multiforme (GBM) | recruiting | Phase 2 | 25 | JenKem Technology Co., Ltd.INDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT04933422 | CM93 Treatment in Subjects With Epidermal Growth Factor Receptor (EGFR)-Modified Recurrent Glioblastoma (rGBM) | not yet recruiting | Phase 1 | 72 | Crimson Biopharm Inc.INDUSTRY | 0 | Aug 21, 2024 | clinicaltrials |
| NCT06524063 | Targeted Survivin DC Cell Injection for the Treatment of GBM | not yet recruiting | Phase 1 | 9 | Beijing Tricision Biotherapeutics IncINDUSTRY | 0 | Jul 29, 2024 | clinicaltrials |
| NCT05990556 | Research on the Safety and Efficacy of Blocking Dural Blood Supply in Glioblastoma Patients | recruiting | N/A | 20 | First Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 1 | Jul 24, 2024 | clinicaltrials |
| NCT06480721 | FET-PET-Guided Management of Pseudoprogression in Glioblastoma(FET-POPPING) | not yet recruiting | N/A | 144 | Veerle RuijtersOTHER | 1 | Jun 28, 2024 | clinicaltrials |
| NCT06477939 | Study of Adding or Not Liposomal Transcrocetin (L-TC) With Concomitant HypoFractionated Radiation ThErapy and TEmozolomide in Newly Diagnosed GLioblastoma (GBM) Patients(THREE-GLEES) | not yet recruiting | Phase 3 | 554 | Institut de cancérologie Strasbourg EuropeOTHER | 1 | Jun 27, 2024 | clinicaltrials |
| NCT06418113 | Neoadjuvant Radio-chemotherapy Safety Pilot Study in Patients With Glioblastoma(GLINERA) | recruiting | Phase 1 | 12 | Hospital San Carlos, MadridOTHER | 1 | May 16, 2024 | clinicaltrials |
| NCT05664464 | Glutamate Inhibitors in Glioblastoma(GLUGLIO) | recruiting | Phase 1 / Phase 2 | 120 | University of ZurichOTHER | 1 | May 10, 2024 | clinicaltrials |
| NCT05768087 | Escalated Dose Proton Therapy Within the Multimodality Treatment of Glioblastoma Patients | recruiting | N/A | 36 | University of AarhusOTHER | 1 | May 9, 2024 | clinicaltrials |
| NCT03899857 | Pembrolizumab for Newly Diagnosed Glioblastoma(PERGOLA) | active not recruiting | Phase 2 | 56 | University of ZurichOTHER | 1 | May 8, 2024 | clinicaltrials |
| NCT06396481 | Clinical Study of Allogeneic Vγ9Vδ2 T Cells in the Treatment of Brain Malignant Glioma(CSAγδTBMG) | not yet recruiting | Early Phase 1 | 25 | Beijing Tiantan HospitalOTHER | 1 | May 2, 2024 | clinicaltrials |
| NCT06368934 | Sub-lobectomy for IDH Wild-type and TERT Promoter Mutant Glioblastoma | not yet recruiting | N/A | 326 | Huashan HospitalOTHER | 1 | Apr 16, 2024 | clinicaltrials |
| NCT05577091 | Tris-CAR-T Cell Therapy for Recurrent Glioblastoma | recruiting | Phase 1 | 10 | Beijing Tiantan HospitalOTHER | 1 | Apr 12, 2024 | clinicaltrials |
| NCT05318612 | Effectiveness of MR-guided LITT Therapy in Irresectable Glioblastoma (EMITT)(EMITT) | active not recruiting | Phase 3 | 238 | Radboud University Medical CenterOTHER | 1 | Apr 10, 2024 | clinicaltrials |
| NCT06327451 | Evaluate the Efficacy and Safety of Atorvastatin Combined With Temozolomide in the Treatment of Glioblastoma | recruiting | Phase 2 | 50 | Tianjin Medical University General HospitalOTHER | 1 | Mar 25, 2024 | clinicaltrials |
| NCT06297512 | Evaluate the Role of Anthracycline After Radio Therapy in Patients With Glioblastoma (pGBM). | recruiting | Phase 2 | 20 | Iacopo SardiOTHER | 1 | Mar 7, 2024 | clinicaltrials |
| NCT06283927 | The RECSUR-study: Resection Versus Best Oncological Treatment for Recurrent Glioblastoma (ENCRAM 2302)(RECSUR) | recruiting | — | 464 | Jasper GerritsenOTHER | 5 | Feb 28, 2024 | clinicaltrials |
| NCT06271421 | NanoTherm In Adjuvant Therapy of Glioblastoma Multiforme(ANCHIALE) | recruiting | N/A | 100 | Poznan University of Medical SciencesOTHER | 1 | Feb 26, 2024 | clinicaltrials |
| NCT06118723 | The SUPRAMAX Study: Supramaximal Resection Versus Maximal Resection for High-Grade Glioma Patients (ENCRAM 2201)(SUPRAMAX) | recruiting | — | 784 | Jasper GerritsenOTHER | 5 | Feb 22, 2024 | clinicaltrials |
| NCT06273176 | The RECMAP-study: Resection With or Without Intraoperative Mapping for Recurrent Glioblastoma(RECMAP) | recruiting | — | 225 | Erasmus Medical CenterOTHER | 5 | Feb 22, 2024 | clinicaltrials |
| NCT06041555 | MRI Guided Radiotherapy and Radiobiological Data: the ISRAR Database (Irm Sequences for Radiobiological Adaptative Radiotherapy)(ISRAR) | recruiting | — | 600 | Hospices Civils de LyonOTHER | 1 | Feb 20, 2024 | clinicaltrials |
| NCT06001281 | Predictive Value of Soluble CD146 in Glioblastoma Patients(MUCIGLIO-01) | recruiting | N/A | 55 | Assistance Publique Hopitaux De MarseilleOTHER | 1 | Feb 2, 2024 | clinicaltrials |
| NCT06220552 | The Efficacy and Safety of Low-dose Radiotherapy Combined With Sintilimab and Temozolomide in Recurrent Glioblastoma | recruiting | Phase 2 | 20 | Fifth Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 1 | Jan 24, 2024 | clinicaltrials |
| NCT06218524 | The Effectiveness of HP and TMZ Synergism on Adult Recurrence GBM | not yet recruiting | Phase 2 | 200 | Southern Medical University, ChinaOTHER | 0 | Jan 23, 2024 | clinicaltrials |
| NCT05908669 | Deuterium Metabolic Imaging to Assess Radiotherapy Changes in Glioblastoma Multiforme | enrolling by invitation | — | 10 | University of AarhusOTHER | 1 | Dec 7, 2023 | clinicaltrials |
| NCT06160596 | Analyzing and Solving Exceptional Long-term Survivors in Solid Tumors With Poor Prognosis(ROSALIND) | recruiting | — | 1,020 | Cure 51OTHER | 1 | Dec 7, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Jan 29, 2025source: clinicaltrials